2025-06-05-Jefferies-固体生物（SLDB）_竞争对手的杜氏肌营养不良症（DMD）功能数据集对Solid_Biosciences公司（SLDB）来说门槛较低_9页_180kb

Equity Research Summary: Solid Bio (SLDB) vs. Competitors

Flash Summary

• Rating: BUY
• Price Target: $15.00 (+291% upside from $3.84)
• Focus: Analysis of competitors RGNX and SRPT in the DMD (Duchenne Muscular Dystrophy) biotech space.

SLDB Highlights

• Stands Out: Superior microdystrophin expression vs. RGNX/SRPT.
• Key Biomarkers: Strong, consistent improvements in muscle health, resilience, and cardiac benefits.
• Strategy: Broader age range (4-<12yo), sicker patients (optimised TTR cutoff), refined functional assessments (time to rise, stride velocity), and later time point evaluation (18mos).
• Unique Tech: Proprietary capsid leads to high levels of microdystrophin expression, protein incorporation, and nNOS activity (enhancing blood flow, reducing inflammation).
• Analyst View: High likelihood of differentiation and success compared to competitors; quality of data potentially leading to better functional outcomes.
• Upcoming Data: 4Q data from Cohort 1 (>-10 pts) is critical.

RGNX Comparison

• Current Performance: Stock down -16% (vs. XBI +1%), driven by concerns including:
  • Lack of correlation proof between microdystrophin expression and clinical function.
  • No functional data for dose DL1.
  • Functional plateau/no deepening improvement.
  • NHS control data potentially inflating treatment effect.
  • Potential impact on accelerated approval path.
  • Safety risks at high doses in younger patients.
• Guidance: Plans pivotal enrollment completion (n=30) for microdystrophin data (H1 2026), BLA filing (mid 2026), potential approval (H1 2027).
• Safety: Looks good (no SAEs/AESI), but uses an immunosuppressive regimen (eculizumab, sirolimus, steroids).

SRPT Comparison

• Competitor program included in assessment of correlation evidence. RGNX/SRPT are mentioned as lacking clear proof.
• SRPT has a market cap of $39.54 and is also rated BUY.

Competitor Comparison: Pfizer (PFE) & Sarepta (SRPT)

• Both rated BUY with targets ($32 and $125+ respectively).
• Jefferies analysts hold convictions in these leaders within their DMD coverage.

Analyst Certification

• All analysts certify views reflect personal views and compensation isn't linked to specific recommendations in this report.

Conclusion

SLDB has a significantly higher potential upside (+291%) due to its differentiated technology and data strategy focusing on broadening patient population and using specific functional endpoints. Analysts believe SLDB has a high chance of success compared to direct competitors like RGNX.